Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisénatide - diabète sucré, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Canada - français - Health Canada

sanofi-aventis canada inc - lixisénatide; lixisénatide - solution - 0.05mg; 0.1mg - lixisénatide 0.05mg; lixisénatide 0.1mg - incretin mimetics

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - lixisenatidum - solution de verser de l'injection - lixisenatidum 0.05 mg, glycerolum (85 per centum), natrii acetas trihydricus, methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - antidiabétique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - lixisenatidum - solution de verser de l'injection - lixisenatidum 0.1 mg, glycerolum (85 per centum), natrii acetas trihydricus, methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - antidiabétique - synthetika

Canada - français - Health Canada

sanofi-aventis canada inc - lixisénatide - solution - 10mcg - lixisénatide 10mcg - incretin mimetics

Canada - français - Health Canada

sanofi-aventis canada inc - lixisénatide - solution - 20mcg - lixisénatide 20mcg - incretin mimetics